Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract

Journal of Immunology

Volumn 166, Issue 5, 2001, Pages 3451-3457

  Gallichan, W S ^a   Woolstencroft, R N ^a   Guarasci, T ^a   McCluskie, M J ^a   Davis, H L ^a   Rosenthal, K L ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN B; IMMUNOGLOBULIN A ANTIBODY; OLIGODEOXYNUCLEOTIDE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; ESTRUS CYCLE; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN PRODUCTION; IMMUNOSTIMULATION; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; VAGINA MUCOSA; VIRUS LOAD; VIRUS REPLICATION;

EID: 0035284751     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.5.3451     Document Type: Article

References (39)

1. Mucosal immunity in the female genital tract: Relevance to vaccination efforts against the human immunodeficiency virus
2. Challenges for vaccination against sexually-transmitted diseases: Induction and long-term maintenance of mucosal immune responses in the female genital tract
3. A rational basis for mucosal vaccination against HIV infection
4. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals
5. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons
6. HIV-1-specific mucosal 1gA in a cohort of HIV-1-resistant Kenyan sex workers
7. + lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi
8. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals
9. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection
10. The association between genital ulcer disease and acquisition of HIV infection in homosexual men
11. CpG motifs in bacterial DNA trigger direct B-cell activation
12. CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL
13. Rapid immune activation by CpG motifs in bacterial DNA: Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway
14. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ
15. Bacterial DNA induces murine intefferon-γ production by stimutation of interleukin-12 and tumor necrosis factor-α
16. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucteotides and bacterial DNA
17. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth
18. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells
19. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
20. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants
21. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants
22. CpG oligodeoxynucteotides act as adjuvants that switch on T helper I (Th1) immunity
23. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice
24. CpG DNA as macosal adjuvant
25. Immunostimulatory DNA is a potent mucosal adjuvant
26. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus
27. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants
28. Herpes simplex virus (HSV) glycoproteins B and K inhibit cell fusion induced by HSV syncytial mutants
29. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B
30. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus
31. Mucosal immunization with a recombinant adenovirus vector induces local and systemic immunity and protection from herpes simplex virus
32. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization
33. Effects of the estrous cycle on local humoral immune responses and protection of intranasally immunized female mice against herpes simplex virus type 2 infection in the genital tract
34. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization
35. The oestrous cycle in the mouse
36. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice
37. Immunoglobulin concentrations and antigen-specific antibody levels in cervicovaginal lavages of rhesus macaques are influenced by the stage of the menstrual cycle
38. Immunoglobulins in human cervico-vaginal secretions
39. Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation